ALTA-1L: Brigatinib vs crizotinib for ALK advanced non small cell lung cancer patients

Bookmark and Share
Published: 23 Sep 2020
Views: 138
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Dr. Sanjay Popat spoke to ecancer about the findings of the ALTA-1L trial presented at the virtual ESMO 2020 meeting this year.

He initially outlined the aims and objectives for the ALTA-1L trial, and gave preliminary results.

Then he went into some detail regarding the efficacy of ALK tyrosine kinase inhibitors (TKIs) against NSCLC (Non-small cell lung cancer) that shows central nervous system (CNS) metastasis.

Dr. Popat further explained the end-points and the efficacy of both brigatinib and crizotinib observed for this trial. He wrapped up by speaking about how these results can affect the future treatment modalities of NSCLC.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.